Evidence map›Paper›PMID 32651913›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2020

Engineering Optogenetic Protein Analogs.

Bei Liu, Daniel J Marston, Klaus M Hahn

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Bei LiuDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.
Daniel J MarstonDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC, USA.
Klaus M HahnDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC, USA. khahn@med.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

Dissecting signaling in vivo via precise control and visualization of protein activityR35GM122596 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Klaus M. Hahn · 2017 to 2026
$7.4M
NIGMS NIH HHS R35 GM122596
6 · The paper itself

Abstract

This chapter provides an overview of the technologies we have developed to control proteins with light. First, we focus on the LOV domain, a versatile building block with reversible photo-response, kinetics tunable through mutagenesis, and ready expression in a broad range of cells and animals. Incorporation of LOV into proteins produced a variety of approaches: simple steric block of the active site released when irradiation lengthened a linker (PA-GTPases), reversible release from sequestration at mitochondria (LOVTRAP), and Z-lock, a method in which a light-cleavable bridge is placed where it occludes the active site. The latter two methods make use of Zdk, small engineered proteins that bind selectively to the dark state of LOV. In order to control endogenous proteins, inhibitory peptides are embedded in the LOV domain where they are exposed only upon irradiation (PKA and MLCK inhibition). Similarly, controlled exposure of a nuclear localization sequence and nuclear export sequence is used to reversibly send proteins into the nucleus. Another avenue of engineering makes use of the heterodimerization of FKBP and FRB proteins, induced by the small molecule rapamycin. We control rapamycin with light or simply add it to target cells. Incorporation of fused FKBP-FRB into kinases, guanine exchange factors, or GTPases leads to rapamycin-induced protein activation. Kinases are engineered so that they can interact with only a specific substrate upon activation. Recombination of split proteins using rapamycin-induced conformational changes minimizes spontaneous reassembly. Finally, we explore the insertion of LOV or rapamycin-responsive domains into proteins such that light-induced conformational changes exert allosteric control of the active site. We hope these design ideas will inspire new applications and broaden our reach towards dynamic biological processes that unfold when studied in vivo.

Indexed as

AnimalsGTP PhosphohydrolasesModels, BiologicalOptogeneticsProtein BindingProtein EngineeringSirolimusTacrolimus Binding ProteinsGTP PhosphohydrolasesSirolimusTacrolimus Binding ProteinsChemogeneticsEngineered extrinsic disorderLOVLOVTRAPOptogeneticsRapRZdkZ-lock

Identifiers

PMID32651913
PMCPMC7448381
OpenAlexW3041259834

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.